PT914158E - Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina - Google Patents

Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina

Info

Publication number: PT914158E
Authority: PT; Portugal
Prior art keywords: compound; salt; antgonist; angiotensin; incorporates
Prior art date: 1996-04-05

Application number

PT97914592T

Other languages

English (en)

Inventor

Hitoshi Ikeda

Takashi Sohda

Norikazu Tamura

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-05

Filing date

1997-04-03

Publication date

2002-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13815962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT914158(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-03 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2002-11-29 Publication of PT914158E publication Critical patent/PT914158E/pt

Links

150000001875 compounds Chemical class 0.000 title 2
102000005862 Angiotensin II Human genes 0.000 title 1
101800000733 Angiotensin-2 Proteins 0.000 title 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title 1
206010022489 Insulin Resistance Diseases 0.000 title 1
229950006323 angiotensin ii Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract 1
GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
229960002632 acarbose Drugs 0.000 abstract 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract 1
KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 abstract 1
HTQMVQVXFRQIKW-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HTQMVQVXFRQIKW-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

PT97914592T 1996-04-05 1997-04-03 Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina PT914158E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP8391796		1996-04-05

Publications (1)

Publication Number	Publication Date
PT914158E true PT914158E (pt)	2002-11-29

Family

ID=13815962

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT97914592T PT914158E (pt)	1996-04-05	1997-04-03	Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina

Country Status (22)

Country	Link
US (2)	US6107323A (pt)
EP (4)	EP0914158B2 (pt)
JP (2)	JPH09323940A (pt)
KR (2)	KR19990087076A (pt)
CN (1)	CN1215338A (pt)
AT (1)	ATE220333T1 (pt)
AU (1)	AU713277B2 (pt)
BR (1)	BR9708517A (pt)
CA (3)	CA2650637A1 (pt)
CY (1)	CY2300B1 (pt)
CZ (1)	CZ297941B6 (pt)
DE (1)	DE69713890T3 (pt)
DK (1)	DK0914158T4 (pt)
ES (1)	ES2175385T5 (pt)
NO (1)	NO321388B1 (pt)
NZ (1)	NZ330774A (pt)
PL (2)	PL189066B1 (pt)
PT (1)	PT914158E (pt)
RU (1)	RU2188013C2 (pt)
SI (1)	SI0914158T2 (pt)
SK (1)	SK283348B6 (pt)
WO (1)	WO1997037688A2 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6268392B1 (en) *	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
AU716519B2 (en) *	1995-06-30	2000-02-24	Laboratoires Merck Sharp & Dohme - Chibret Snc	Method of treating renal disease using an ace inhibitor and an A II antagonist
US5798375A (en) *	1995-07-03	1998-08-25	Sankyo Company, Limited	Treatment of arteriosclerosis and xanthoma
PL189066B1 (pl) *	1996-04-05	2005-06-30	Takeda Pharmaceutical	Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz stosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II
DE69734405T2 (de)	1996-07-15	2006-08-03	Sankyo Co., Ltd.	Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose
JP2008094852A (ja) *	1996-07-15	2008-04-24	Daiichi Sankyo Co Ltd	医薬
WO1999009965A2 (en) *	1997-08-21	1999-03-04	Takeda Chemical Industries, Ltd.	Anti-inflammatory agent
US7105552B2 (en)	1998-05-08	2006-09-12	Theracos, Inc.	Heterocyclic analogs of diphenylethylene compounds
DK1140061T3 (da)	1998-12-23	2003-08-25	Orphan Medical Inc	Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
US6756360B1 (en)	1998-12-24	2004-06-29	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
WO2000043006A1 (en) *	1999-01-19	2000-07-27	Sankyo Company, Limited	Inhibitor for nerve cell death due to glutamic acid cytotoxicity
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
US7407978B2 (en) *	1999-04-06	2008-08-05	Theracos, Inc.	Heterocyclic analogs of diphenylethylene compounds
EP1197223B1 (en) *	1999-04-28	2005-02-16	Takeda Pharmaceutical Company Limited	Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
WO2001005428A1 (en) *	1999-07-21	2001-01-25	Takeda Chemical Industries, Ltd.	Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
JP4000505B2 (ja) *	1999-12-01	2007-10-31	第一三共株式会社	緑内障を治療するための併用剤
CA2400124C (en) *	2000-02-18	2010-12-14	Kazuaki Ikeya	Tnf-.alpha. inhibitors
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
AR033390A1 (es) *	2000-08-22	2003-12-17	Novartis Ag	Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
WO2002017913A1 (en) *	2000-08-30	2002-03-07	Sankyo Company, Limited	Medicinal compositions for preventing or treating heart failure
EP1370210A4 (en) *	2001-02-07	2004-08-18	Mclean Hospital Corp	HYPOCHOLESTEROLEMIANTS USED TO TREAT PSYCHOLOGICAL AND COGNITIVE DISORDERS
US20030078190A1 (en) *	2001-05-25	2003-04-24	Weinberg Marc S.	Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
GB0113570D0 (en)	2001-06-04	2001-07-25	Hewlett Packard Co	Audio-form presentation of text messages
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
WO2003047573A1 (en) *	2001-12-03	2003-06-12	Takeda Chemical Industries, Ltd.	Insulin resistance improving agents
JP4484427B2 (ja) *	2001-12-03	2010-06-16	武田薬品工業株式会社	インスリン抵抗性改善剤
MY131170A (en) *	2002-03-28	2007-07-31	Nissan Chemical Ind Ltd	Therapeutic agent for glomerular disease
US20030229007A1 (en) *	2002-05-30	2003-12-11	Roberto Levi	Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
US7232828B2 (en) *	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2003256419A1 (en) *	2002-08-21	2004-03-11	Merck & Co., Inc.	Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
EP1579872B8 (en) *	2002-12-27	2012-11-07	Takeda Pharmaceutical Company Limited	Body weight gain inhibitor
HRP20050655A2 (en) *	2003-01-16	2006-05-31	Boehringer Ingelheim International Gmbh	Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
DE10301371A1 (de) *	2003-01-16	2004-08-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
WO2005011736A1 (ja) *	2003-07-30	2005-02-10	Tohoku Techno Arch Co., Ltd.	アルツハイマー病の予防および／または治療剤
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
US20050250734A1 (en) *	2003-11-07	2005-11-10	The Procter & Gamble Company	Compositions, kits, and methods for the treatment of conditions associated with elevated cholesterol levels
WO2005070398A2 (en) *	2004-01-23	2005-08-04	Ranbaxy Laboratories Limited	Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
US20060039890A1 (en) *	2004-08-20	2006-02-23	Renshaw Perry F	Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
KR20070073872A (ko) *	2004-10-07	2007-07-10	다케다 야쿠힌 고교 가부시키가이샤	대사 증후군의 예방 또는 치료용 제제
ES2371145T3 (es) *	2005-01-26	2011-12-27	Lek Pharmaceuticals D.D.	Nueva composición farmacéutica que contiene candesartán cilexetilo como sustancia cristalina lipófila.
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1863801B1 (en) *	2005-03-30	2010-09-29	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof
KR101126383B1 (ko)	2007-02-07	2012-04-12	교와 핫꼬 기린 가부시키가이샤	3환계 화합물
DE102007011485A1 (de)	2007-03-07	2008-09-11	Grünenthal GmbH	Darreichungsform mit erschwertem Missbrauch
US9066936B2 (en) *	2007-03-28	2015-06-30	Takeda Pharmaceutical Company Limited	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
US20090074831A1 (en) *	2007-09-18	2009-03-19	Robert Falotico	LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
WO2009088006A1 (ja) *	2008-01-10	2009-07-16	Daiichi Sankyo Company, Limited	併用医薬
KR101616246B1 (ko)	2008-01-25	2016-05-02	그뤼넨탈 게엠베하	약제학적 투여형
US20110117194A1 (en)	2008-04-29	2011-05-19	Hanall Biopharma Co., Ltd.	Pharmaceutical formulation containing angiotensin-ii receptor blocker
AU2009243681B2 (en)	2008-05-09	2013-12-19	Grunenthal Gmbh	Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
TWI473628B (zh)	2009-07-22	2015-02-21		用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2011009602A1 (en)	2009-07-22	2011-01-27	Grünenthal GmbH	Hot-melt extruded controlled release dosage form
CA2808219C (en)	2010-09-02	2019-05-14	Gruenenthal Gmbh	Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en)	2010-09-02	2012-03-08	Grünenthal GmbH	Tamper resistant dosage form comprising an anionic polymer
ES2648129T3 (es)	2011-07-29	2017-12-28	Grünenthal GmbH	Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
AU2012289764B2 (en)	2011-07-29	2017-03-02	Grünenthal GmbH	Tamper-resistant tablet providing immediate drug release
US20130225697A1 (en)	2012-02-28	2013-08-29	Grunenthal Gmbh	Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl)	2012-04-18	2018-12-31	Grünenthal GmbH	Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2873422A4 (en) *	2012-07-10	2015-12-30	Takeda Pharmaceutical	PHARMACEUTICAL PREPARATION FOR INJECTION
JP6466417B2 (ja)	2013-05-29	2019-02-06	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en)	2013-05-29	2019-08-15	Grunenthal Gmbh	Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja)	2013-07-12	2019-01-09	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP3073994A1 (en)	2013-11-26	2016-10-05	Grünenthal GmbH	Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en)	2014-05-12	2017-03-22	Grünenthal GmbH	Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru)	2014-05-26	2017-05-31	Грюненталь Гмбх	Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
BR112017021475A2 (pt)	2015-04-24	2018-07-10	Gruenenthal Gmbh	forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017042325A1 (en)	2015-09-10	2017-03-16	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0238580B2 (ja) *	1981-06-02	1990-08-31	Takeda Chemical Industries Ltd	Bariooruaminnonnchikanjudotai*sonoseizohooyobyoto
EP0400835A1 (en) *	1989-05-15	1990-12-05	Merck & Co. Inc.	Substituted benzimidazoles as angiotensin II antagonists
DE69100282T3 (de) *	1990-02-09	2001-01-11	Pharmacia & Upjohn Co., Kalamazoo	Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
US5196444A (en) *	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
BR9106438A (pt) *	1990-05-11	1993-05-18	Pfizer	Composicoes terapeuticas sinergisticas e processos
US5298497A (en) *	1990-05-15	1994-03-29	E. R. Squibb & Sons, Inc.	Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) *	1990-05-15	2002-07-23	James L. Bergey	Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
AU656551B2 (en) *	1990-12-14	1995-02-09	Smithkline Beecham Corporation	Angiotensin II receptor blocking compositions
AU1256692A (en) *	1991-02-06	1992-09-07	Schering Corporation	Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
EP0503838A3 (en) *	1991-03-08	1992-10-07	Merck & Co. Inc.	Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
US5162340A (en) *	1991-05-10	1992-11-10	Merck & Co., Inc.	Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists
HU9203780D0 (en) *	1991-12-12	1993-03-29	Sandoz Ag	Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
NZ251741A (en) *	1992-04-13	1997-06-24	Zeneca Ltd	Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity
US5266583A (en) *	1992-09-01	1993-11-30	Merck & Co., Inc.	Angitotensin II antagonist
DE4315349A1 (de) *	1992-10-06	1994-11-10	Thomae Gmbh Dr K	Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5300668A (en) *	1993-03-10	1994-04-05	Pfizer Inc.	Certain esters of 1-(4-X-methylphenyl)cyclopent-3-ene-1-carboxylic acid, wherein X is a trialkylsilyloxy, bromo or hydroxy group, as intermediates
JP3057471B2 (ja) *	1993-06-07	2000-06-26	武田薬品工業株式会社	アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
CA2125251C (en) *	1993-06-07	2005-04-26	Yoshiyuki Inada	A pharmaceutical composition for angiotensin ii-mediated diseases
EP0629408A1 (en) *	1993-06-16	1994-12-21	LABORATOIRES MERCK, SHARP & DOHME-CHIBRET	Combination of angiotensin converting enzyme inhibitors and AII antagonists
EP0635263A3 (en) *	1993-06-28	1995-09-27	American Cyanamid Co	Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
CA2186606A1 (en) *	1994-03-29	1995-10-05	Edward B. Nelson	Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
GB9406573D0 (en) *	1994-03-31	1994-05-25	Merck Sharp & Dohme	Medicaments
FR2733911B1 (fr) *	1995-05-09	1998-05-29	Takeda Chemical Industries Ltd	Composition pharmaceutique pour maladies renales ou cardio-vasculaires
FR2735365B1 (fr) *	1995-06-14	1997-09-05	Sanofi Sa	Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
AU716519B2 (en) *	1995-06-30	2000-02-24	Laboratoires Merck Sharp & Dohme - Chibret Snc	Method of treating renal disease using an ace inhibitor and an A II antagonist
US5798375A (en) *	1995-07-03	1998-08-25	Sankyo Company, Limited	Treatment of arteriosclerosis and xanthoma
PL189066B1 (pl) *	1996-04-05	2005-06-30	Takeda Pharmaceutical	Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz stosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II

1997
- 1997-04-03 PL PL97329188A patent/PL189066B1/pl not_active IP Right Cessation
- 1997-04-03 EP EP97914592A patent/EP0914158B2/en not_active Expired - Lifetime
- 1997-04-03 CN CN97193515A patent/CN1215338A/zh active Pending
- 1997-04-03 US US08/836,784 patent/US6107323A/en not_active Expired - Lifetime
- 1997-04-03 EP EP01124024A patent/EP1192951A3/en not_active Withdrawn
- 1997-04-03 PL PL367915A patent/PL193365B1/pl not_active IP Right Cessation
- 1997-04-03 SI SI9730391T patent/SI0914158T2/sl unknown
- 1997-04-03 EP EP10173392A patent/EP2253327A1/en not_active Withdrawn
- 1997-04-03 WO PCT/JP1997/001149 patent/WO1997037688A2/en not_active Ceased
- 1997-04-03 DK DK97914592T patent/DK0914158T4/da active
- 1997-04-03 CA CA002650637A patent/CA2650637A1/en not_active Abandoned
- 1997-04-03 AU AU21780/97A patent/AU713277B2/en not_active Ceased
- 1997-04-03 CA CA002241466A patent/CA2241466C/en not_active Expired - Fee Related
- 1997-04-03 PT PT97914592T patent/PT914158E/pt unknown
- 1997-04-03 DE DE69713890T patent/DE69713890T3/de not_active Expired - Lifetime
- 1997-04-03 KR KR1019980706462A patent/KR19990087076A/ko not_active Ceased
- 1997-04-03 KR KR1020057007489A patent/KR20050047560A/ko not_active Ceased
- 1997-04-03 CA CA002577233A patent/CA2577233C/en not_active Expired - Fee Related
- 1997-04-03 RU RU98119885/14A patent/RU2188013C2/ru not_active IP Right Cessation
- 1997-04-03 ES ES97914592T patent/ES2175385T5/es not_active Expired - Lifetime
- 1997-04-03 AT AT97914592T patent/ATE220333T1/de active
- 1997-04-03 CZ CZ0288698A patent/CZ297941B6/cs not_active IP Right Cessation
- 1997-04-03 EP EP07009568A patent/EP1813286A3/en not_active Withdrawn
- 1997-04-03 NZ NZ330774A patent/NZ330774A/xx not_active IP Right Cessation
- 1997-04-03 SK SK1278-98A patent/SK283348B6/sk not_active IP Right Cessation
- 1997-04-03 BR BR9708517A patent/BR9708517A/pt not_active IP Right Cessation
- 1997-04-04 JP JP9086484A patent/JPH09323940A/ja active Pending
1998
- 1998-09-07 NO NO19984123A patent/NO321388B1/no not_active IP Right Cessation
2000
- 2000-04-18 US US09/551,546 patent/US6432996B1/en not_active Expired - Fee Related
2002
- 2002-10-22 CY CY0200060A patent/CY2300B1/xx unknown
2008
- 2008-04-21 JP JP2008110085A patent/JP2008195736A/ja active Pending

Also Published As

Publication number	Publication date
DE69713890T3 (de)	2006-09-07
EP1813286A2 (en)	2007-08-01
EP0914158B1 (en)	2002-07-10
SI0914158T1 (en)	2002-12-31
US6107323A (en)	2000-08-22
NZ330774A (en)	1999-06-29
EP1192951A2 (en)	2002-04-03
WO1997037688A2 (en)	1997-10-16
NO321388B1 (no)	2006-05-02
EP0914158A2 (en)	1999-05-12
CA2577233C (en)	2009-08-18
JP2008195736A (ja)	2008-08-28
NO984123L (no)	1998-09-07
ATE220333T1 (de)	2002-07-15
PL193365B1 (pl)	2007-02-28
CA2241466A1 (en)	1997-10-16
KR20050047560A (ko)	2005-05-20
EP1813286A3 (en)	2008-04-16
SK127898A3 (en)	1999-05-07
WO1997037688A3 (en)	1998-03-05
US6432996B1 (en)	2002-08-13
CA2650637A1 (en)	1997-10-16
CY2300B1 (en)	2003-07-04
JPH09323940A (ja)	1997-12-16
PL189066B1 (pl)	2005-06-30
DK0914158T3 (da)	2002-10-14
RU2188013C2 (ru)	2002-08-27
EP2253327A1 (en)	2010-11-24
CZ288698A3 (cs)	1998-12-16
DE69713890D1 (de)	2002-08-14
CN1215338A (zh)	1999-04-28
AU713277B2 (en)	1999-11-25
CA2241466C (en)	2007-05-22
CA2577233A1 (en)	1997-10-16
SI0914158T2 (sl)	2006-04-30
PL329188A1 (en)	1999-03-15
ES2175385T5 (es)	2006-06-01
CZ297941B6 (cs)	2007-05-02
KR19990087076A (ko)	1999-12-15
ES2175385T3 (es)	2002-11-16
NO984123D0 (no)	1998-09-07
AU2178097A (en)	1997-10-29
EP1192951A3 (en)	2004-04-21
DK0914158T4 (da)	2006-03-06
BR9708517A (pt)	1999-08-03
DE69713890T2 (de)	2002-11-21
EP0914158B2 (en)	2006-01-25
SK283348B6 (sk)	2003-06-03

Publication	Publication Date	Title
PT914158E (pt)	2002-11-29	Combinacao farmaceutica que incorpora um composto que possui actividade antagonista da angiotensina ii e um composto que aumenta a sensibilidade a insulina
DE69727956D1 (de)	2004-04-08	Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
BRPI0310021B8 (pt)	2021-05-25	composição farmacêutica compreendendo 4-[[4-[(2,4,6-trimetilfenil)amino]-2-pirimidinil]amino]benzonitrilo ou um sal de adição farmaceuticamente aceitável de mesmo
ATE530530T1 (de)	2011-11-15	Diaminopyrimidincarbonsäureamidderivat
BR0314918A (pt)	2005-08-02	Compostos de purina e uso dos mesmos como ligantes de receptor canabinóide
DE69631246D1 (de)	2004-02-05	Rekombinante pockenviren des waschbaers sowie ihre verwendung als ein effektiver impfstoff gegen eine infektion mit immunschwaecheviren der katze
DK0392959T3 (da)	1999-03-29	Anvendelse af Sertindole til behandling af skizofreni
TR199901417T2 (xx)	1999-10-21	Analjezik etkisi olan yeni bile�imler.
DE69727922D1 (de)	2004-04-08	Schnell zerfallende orale dosierungsform
DE50005529D1 (de)	2004-04-08	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE354362T1 (de)	2007-03-15	Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
TR200606411T1 (tr)	2007-01-22	Vajinite karşı bir triazol içeren bileşimler.
BG106391A (bg)	2002-09-30	Приложение на cgrp-антагонисти и инхибитори на освобождаването на cgrp за лечение на горещи вълни при менопауза
EP1452176A4 (en)	2009-01-21	AGENTS FOR IMPROVING THE STATE OF RESISTANCE OF INSULIN
ES2192779T3 (es)	2003-10-16	Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.
DE602004016968D1 (de)	2008-11-20	Auf substanz p basierende radiomarkierte konjugate und deren gebrauch
ATE264309T1 (de)	2004-04-15	Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
BR0318352A (pt)	2006-07-25	filtro microbicida de ar para uso com uma passagem de ar e máscara facial
BR0317947A (pt)	2005-11-29	Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes
ATE326451T1 (de)	2006-06-15	Chinazolin derivate und therapeutische verwendungen davon
DK1331940T3 (da)	2006-08-14	Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
DE602004018622D1 (de)	2009-02-05	Pharmazeutische zusammensetzung enthaltend 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylessigsäure
NO20071889L (no)	2007-06-26	Middel for profylakse eller behandling av stoffskiftesyndrom.
ATE340567T1 (de)	2006-10-15	Transdermales therapeutisches system zur verabreichung des partiellen dopamin-d2-agonisten aripiprazol
ATE353642T1 (de)	2007-03-15	Verwendung von hypoestoxiden als antiparasitäre mittel